-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IBI-343 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IBI-343 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IBI-343 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: IBI-343 is...
-
Track & Monitor
Immuno-oncology in pharma: immunotherapy radiotherapy combination
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s immunotherapy radiotherapy combination segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Company Profile
Nanobiotix SA – Company Profile
Nanobiotix SA (Nanobiotix) carries out designs and manufactures nanomedicines for the treatment of cancer. The company is evaluating its lead product candidate NBTXR3 against soft tissue sarcoma, esophageal, pancreatic, liver, rectal, prostate, head and neck cancers; non-small cell lung cancer (NSCLC); recurrent head and neck, lung and liver metastasis cancers. Its product candidate is a first-in-class radiotracer composed of hafnium oxide nanoparticles and is activated by radiation therapy to destroy tumors. The company markets NBTXR3 under the brand name Hensify...
Add to Basket -
Track & Monitor
Key innovators in cancer radiotherapy
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the cancer radiotherapy segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based on the availability...
-
Product Insights
Nanobiotix SA Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Nanobiotix SA Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Nanobiotix SA (Nanobiotix) designs and manufactures nanomedicines for the treatment of cancer. The company is evaluating its lead product candidate NBTXR3 against soft tissue sarcoma, esophageal, pancreatic, liver, rectal, prostate, head and neck cancers; non-small cell lung cancer (NSCLC); recurrent head and neck, lung and liver metastasis cancers. Its product candidate is a first-in-class radiohancer composed of hafnium oxide nanoparticles...
-
Product Insights
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in the later stages of the disease. The signs and symptoms include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody...
-
Track & Monitor
Targeted therapies in Pharmaceuticals: Photodynamic cancer therapy drugs
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NBTXR-3
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NBTXR-3 Drug Details NBTXR-3 is under development for the treatment of head and neck cancer...
-
Product Insights
Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. The Melanoma pipeline market research report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Cervical Cancer Drugs Market Report Overview Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Its symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding, spotting between periods, and having longer or heavier (menstrual) periods than usual. Key Targets Programmed Cell Death Protein 1, Human Papillomavirus Protein E7, Programmed Cell Death 1 Ligand 1, Human Papillomavirus Protein E6, Cytotoxic T Lymphocyte Protein 4, Vascular Endothelial...